Propensity score analysis comparing survival between definitive chemoradiotherapy and esophagectomy with adjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2022
Historique:
received: 10 10 2021
accepted: 29 06 2022
entrez: 13 10 2022
pubmed: 14 10 2022
medline: 18 10 2022
Statut: epublish

Résumé

The purpose of the current study is to compare definitive chemoradiotherapy and esophagectomy with adjuvant chemoradiotherapy in patients with cT1-3/N0-3 esophageal squamous cell carcinoma in survival. Records from 2008 to 2014 of 4931 patients with clinical T1-3/N0-3 esophageal squamous cell carcinoma receiving definitive chemoradiotherapy or esophagectomy with adjuvant chemoradiotherapy were obtained from the Taiwan Cancer Registry. Univariable and multivariable analyses were performed and propensity score matching was used to minimize the bias. Overall survival was compared between definitive chemoradiotherapy and esophagectomy with adjuvant chemoradiotherapy, and also in the three different clinical stages. Definitive chemoradiotherapy was performed on 4381 patients, and 550 patients received esophagectomy adjuvant chemoradiotherapy. Each group produced 456 patients for comparison after propensity score matching. The 1-year, 2-year, and 3-year overall survival rates for matched patients in with definitive chemoradiotherapy group were 57.18%, 31.92%, and 23.8%. The 1-year, 2-year, and 3-year overall survival rates for matched patients treated in the esophagectomy with adjuvant chemoradiotherapy group were 72.35%, 45.74%, and 34.04%(p<0.0001). In multivariable analysis, treatment modality was an independent prognostic factor. Esophagectomy with adjuvant chemoradiotherapy provided better survival outcome than definitive chemoradiotherapy for patients with clinical stage II/III disease. As for patients with clinical stage I disease, there was no significant survival difference between definitive chemoradiotherapy and esophagectomy with adjuvant chemoradiotherapy. Esophagectomy with adjuvant chemoradiotherapy provided better survival than definitive chemoradiotherapy in clinical II/III esophageal squamous cell carcinoma. However, more data are needed to conduct a convincing conclusion in clinical stage I patients.

Identifiants

pubmed: 36227954
doi: 10.1371/journal.pone.0271338
pii: PONE-D-21-32509
pmc: PMC9560125
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0271338

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

World J Gastroenterol. 2017 Jan 21;23(3):540-546
pubmed: 28210091
Ann Thorac Surg. 2019 Apr;107(4):1060-1067
pubmed: 30571951
Br J Cancer. 2017 Mar 14;116(6):709-716
pubmed: 28196063
Cancer Med. 2018 Sep;7(9):4193-4201
pubmed: 30047253
Int J Clin Oncol. 2018 Jun;23(3):458-465
pubmed: 29435872
Ann Surg Oncol. 2010 Jul;17(7):1721-4
pubmed: 20369299
Lancet Oncol. 2011 Jul;12(7):681-92
pubmed: 21684205
J Clin Oncol. 2005 Apr 1;23(10):2310-7
pubmed: 15800321
Medicine (Baltimore). 2016 Mar;95(10):e3018
pubmed: 26962818
Cancer Med. 2016 Dec;5(12):3371-3377
pubmed: 27925455
Br J Surg. 2014 Apr;101(5):502-10
pubmed: 24615406
J Clin Oncol. 2007 Apr 1;25(10):1160-8
pubmed: 17401004
Br J Surg. 2019 Feb;106(3):255-262
pubmed: 30395362
Drugs Aging. 2015 Jun;32(6):487-93
pubmed: 26038198
J Natl Compr Canc Netw. 2014 Dec;12(12):1697-705
pubmed: 25505210
Br J Surg. 2017 Jan;104(1):90-97
pubmed: 27859017
J Thorac Cardiovasc Surg. 2003 Nov;126(5):1590-6
pubmed: 14666038
Cancer. 2001 Jun 15;91(12):2423-30
pubmed: 11413534
J Natl Compr Canc Netw. 2019 Jul 1;17(7):855-883
pubmed: 31319389
Dis Esophagus. 2017 Feb 1;30(2):1-7
pubmed: 27868290
Ann Oncol. 2013 Jan;24(1):165-71
pubmed: 22887465
J Thorac Cardiovasc Surg. 2015 Apr;149(4):1006-14; discussion 1014- 5.e4
pubmed: 25752374
Ann Surg Oncol. 2013 Sep;20(9):3023-30
pubmed: 23525703
Med Oncol. 2015 Jan;32(1):417
pubmed: 25479943
JAMA. 1999 May 5;281(17):1623-7
pubmed: 10235156
Neoplasma. 2014;61(6):732-8
pubmed: 25150318
N Engl J Med. 2012 May 31;366(22):2074-84
pubmed: 22646630
J Clin Oncol. 2002 Mar 1;20(5):1167-74
pubmed: 11870157
Ann Surg. 2016 Jul;264(1):100-6
pubmed: 26649580

Auteurs

Yi-Lin Chang (YL)

Division of General Surgery, Department of Surgery, Changhua Christian Hospital, Changhua, Taiwan.

Ya-Fu Cheng (YF)

Division of Thoracic Surgery, Department of Surgery, Changhua Christian Hospital, Changhua, Taiwan.

Hui-Shan Chen (HS)

Department of Health Care Administration, Chang Jung Christian University, Tainan, Taiwan.

Siao-Chi Wu (SC)

Institute of Health and Welfare Policy, National Yang-Ming University, Taipei, Taiwan.

Wei-Heng Hung (WH)

Division of Thoracic Surgery, Department of Surgery, Changhua Christian Hospital, Changhua, Taiwan.

Heng-Chung Chen (HC)

Division of Thoracic Surgery, Department of Surgery, Changhua Christian Hospital, Changhua, Taiwan.

Chang-Lun Huang (CL)

Division of Thoracic Surgery, Department of Surgery, Changhua Christian Hospital, Changhua, Taiwan.

Ching-Yuan Cheng (CY)

Division of Thoracic Surgery, Department of Surgery, Changhua Christian Hospital, Changhua, Taiwan.

Bing-Yen Wang (BY)

Division of Thoracic Surgery, Department of Surgery, Changhua Christian Hospital, Changhua, Taiwan.
Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung, Taiwan.
School of Medicine, Chung Shan Medical University, Taichung, Taiwan.
School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
Institute of Genomics and Bioinformatics, National Chung Hsing University, Taichung, Taiwan.
Center for General Education, Ming Dao University, Changhua, Taiwan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH